This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
JACC Specialty Journals
JACC: CardioOncology - Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial
Released: Nov 17, 2020
Commentary by Dr. Ileana L. Piña
JACC: CardioOncology - Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial
00:00:00
